Compare TRIP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIP | REPL |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2011 | 2018 |
| Metric | TRIP | REPL |
|---|---|---|
| Price | $7.28 | $21.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 8 |
| Target Price | $11.57 | ★ $23.33 |
| AVG Volume (30 Days) | ★ 5.7M | 3.2M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $513.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.78 | $1.50 |
| 52 Week High | $15.73 | $23.64 |
| Indicator | TRIP | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 70.94 |
| Support Level | N/A | $7.19 |
| Resistance Level | $11.53 | N/A |
| Average True Range (ATR) | 0.52 | 1.67 |
| MACD | -0.20 | 0.42 |
| Stochastic Oscillator | 12.12 | 82.86 |
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.